FEATURE ARTICLES

Will GSK’s Deal With Novartis Pay Off For Its Vaccine Aspirations?
Will GSK’s Deal With Novartis Pay Off For Its Vaccine Aspirations?

Top GSK executives such as Luc Debruyne, president of GSK Vaccines (pictured), talk about the company’s vaccine and oncology aspirations.

More featured articles

ALSO IN THIS MONTH'S ISSUE:

  • Rx Industry Vulnerable On Generic Delay In Fall
    Rx Industry Vulnerable On Generic Delay In Fall

    There is growing chatter among congressional aides that the pharma industry should ante up some resources to help address some yet-unresolved healthcare issues.

  • Drug Company Discovery & Commercialization: An Election Year Analogy
    Drug Company Discovery & Commercialization: An Election Year Analogy

    As I consider the move from clinical to commercialization, it reminds me of the American electoral system – primary elections that are tightly focused and a general election where a candidate faces a vastly broader audience and has the opportunity to engage on a much larger stage and with far greater impact.

  • Companies To Watch: Quark Pharmaceuticals
    Companies To Watch: Quark Pharmaceuticals

    Having passed through much of the proof-of-concept gauntlet, the company and its products’ next big test will come in its Phase 3 trials, where the concept meets uncertainty at the macro scale.

  • The Increasing Importance Of Real-World Evidence In Drug Development
    The Increasing Importance Of Real-World Evidence In Drug Development

    Market access is all about getting the right drugs to the right patients at the right time and for the right price. But to do so, every pharma or biotech company must face a mounting set of challenges, including, most prominently, high research costs and tighter budgets.

  • Where Will The Next Biopharma Breakthrough Come From?
    Where Will The Next Biopharma Breakthrough Come From?

    Ever heard of the company Galvani Bioelectronics? The name probably sounds familiar because the company was recently the subject of nearly every news media outlet, including the Wall Street Journal.

More from Life Science Leader

WEB-EXCLUSIVE EDITORIAL

  • Data-Driven Personas Help Break Life Sciences Out Of The Compliance Slump
    Data-Driven Personas Help Break Life Sciences Out Of The Compliance Slump

    When life sciences and healthcare organizations look at their medication compliance numbers, they often feel like a baseball manager with a slumping hitter. The data shows that the hitter is 0 for 22, with 10 strikeouts, over the last few games. But it offers little guidance on why the player doesn’t appear to be able to hit water if he fell out of a boat or what the manager can do to get to the hitter back on track again.

  • Combining Human-Centered Design And Big Data In Pharma
    Combining Human-Centered Design And Big Data In Pharma

    Data is exponentially increasing while habits remain steeped in legacy systems and the past when it comes to safety and pharmacovigilance (PV) in the pharmaceutical ecosystem.

  • Three Keys To Mitigating Risk In Adaptive Trials
    Three Keys To Mitigating Risk In Adaptive Trials

    About 50 percent of all Phase III trials fail. That is an expensive problem for the pharmaceutical industry, as a 2014 study by the U.S. Department of Health and Human Services estimated the average cost of a Phase III trial to be $20 million.

  • Letting The Patient Voice Take Root Within A Company
    Letting The Patient Voice Take Root Within A Company

    As the biopharmaceutical industry is becoming more comfortable with the principle of calibrating its efforts with a focus on patients, one question is beginning to float to the top: What strategy would generate a maximum amount of patient-centricity? In recent decades, focus groups, advisory boards, and various patient-engagement initiatives have emerged and informed mainly post-approval activities. Patient leadership councils (PLCs) are now starting to take patient engagement to unprecedented levels. Patient influence is forecast to rise.

  • 5 Ways To Raise The Profile Of Your Corporate Information Center
    5 Ways To Raise The Profile Of Your Corporate Information Center

    As head of global information for a major biopharmaceutical company, I try to anticipate what might be the next service line that we should provide to our internal customers and what might be the next big thing in terms of information provision, rights requirements, and the like. To ensure that my corporate information center runs optimally, there are five areas of improvement I continue to focus on, which not only keeps my team current, highly-skilled, collaborative and empowered, but also demonstrates a positive ROI for our parent organization.

More web-exclusive editorial

CUTTING ROOM FLOOR EDITORIAL

More cutting room floor editorial

LIFE SCIENCE TRAINING INSTITUTE COURSES

Reacting to “Human Error” – Moving Beyond “Retraining” As A Response September 27, 2016
1pm-2:30pm EDT, Online Training
New Pharma Compliant Google Ad Formats – Implementation Tips For Success September 29, 2016
1pm-2:30pm EDT, Online Training
Pediatric Clinical Trials: Special Considerations and Requirements October 6, 2016
1pm-2:30pm EDT, Online Training
Medical Device Design Controls 101 – A Practical Crash Course October 12, 2016
1pm-2:30pm EDT, Online Training
More training courses

SEPTEMBER 2016 DIGITAL EDITION

2016 CRO AWARDS SPECIAL EDITION

2016 CMO AWARDS SPECIAL EDITION

BLOGS

  • Can A Better Patient Experience Lead To A Better Patient Outcome?
    Can A Better Patient Experience Lead To A Better Patient Outcome?

    My colleague, Ed Miseta, chief editor of Clinical Leader, recently asked, “Can Better Patient Experiences Lead To Better Medicines?” via an article he developed from an interview with Thomas Goetz, cofounder of Iodine, a digital health company. According to Miseta, Goetz is attempting to turn patient experiences into better medicines and is combining data and design to help patients locate the best treatments based on preferences, demographics, and experiences. But truthfully it wasn’t Goetz’s work that intrigued me (but still worth your reading about), but rather Miseta’s question.

  • IO: Science Still Drives The Business
    IO: Science Still Drives The Business

    How much science does a business person need to know? In this industry, the more the better. Without at least an excellent layperson’s understanding of the company’s scientific underpinnings, a life science executive will remain vulnerable to the greatest of all hazards in managing the business — today’s news.

More blogs

 UPCOMING EVENTS

Bad Standard Operating Procedures (SOPs) = Bad Training: Garbage In, Garbage Out September 26, 2016
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
Reacting to “Human Error” – Moving Beyond “Retraining” As A Response September 27, 2016
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
PharmAccess Leaders Forum Autumn 2016 September 27, 2016
Berlin
The HireLifeScience.com Career Fair 2016 September 27, 2016
Edison, NJ
More events